结构正常心脏室性心动过速的导管消融:适应证、策略与结局(第一部分)
本文综述结构正常心脏室性心动过速(VT)的病理生理、机制与管理,重点讨论导管消融的作用。此类患者心脏性猝死风险低,通常无需植入ICD,消融主要用于症状控制或治疗心动过速性心肌病,并可能根治。
要点
- 结构正常心脏的VT或室早猝死风险低,通常无ICD指征。
- 导管消融用于症状管理或治疗心动过速性心肌病,可能根治。
- 结构心脏病VT需ICD,消融作为辅助治疗减少ICD治疗。
核心结论
- 结构正常心脏的VT患者猝死风险低,导管消融可用于症状管理或治疗心动过速性心肌病,且可能根治。
研究设计与样本
- 本文为综述,讨论结构正常心脏VT的病理生理、机制和管理以及导管消融的作用。
主要发现
- 结构正常心脏的VT或室早心脏性猝死风险低,通常无ICD指征。
- 结构心脏病VT患者猝死风险高,通常需ICD,消融作为辅助治疗减少ICD治疗。
临床怎么用
- 结构正常心脏VT患者应评估症状及心动过速性心肌病,考虑导管消融而非ICD。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Catheter ablation of ventricular tachycardia (VT) is being increasingly performed; yet, there is often confusion regarding indications, outcomes, and how to identify those patient populations most likely to benefit. The management strategy differs between those with structural heart disease and those without. For the former, an implantable cardioverter-defibrillator (ICD) is typically required due to an elevated risk for sudden cardiac death, and catheter ablation can be used as adjunctive therapy to treat or prevent repetitive ICD therapies. In contrast, VT or premature ventricular contractions in the setting of a structurally normal heart carries a low risk for sudden cardiac death; accordingly, there is typically no indication for an ICD. In these patients, catheter ablation is considered for symptom management or to treat tachycardiomyopathy and is potentially curative. Here, the authors discuss the pathophysiology, mechanism, and management of VT that occurs in the setting of a structurally normal heart and the role of catheter ablation.
引用
- Dukkipati SR, Choudry S, Koruth JS, et al. Catheter Ablation of Ventricular Tachycardia in Structurally Normal Hearts: Indications, Strategies, and Outcomes-Part I. J Am Coll Cardiol. 2017. PMID: 29216987. doi:10.1016/j.jacc.2017.10.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。